Less than 5 percent of interventional cardiologists are women. A study has found that changing hours, male-dominant culture and radiation are deterrents.
Stanford scientists have dug up a defect at the heart of rheumatoid arthritis: a faulty "anchor" that should be tethering a key molecule to the spot inside immune cells where it has to be in order to do its job. It seems this defect can be reversed with a not yet commercially available small-molecule drug.
More than 50,000 pregnant women per year experience life-threatening complications of pregnancy and childbirth, but no one understands why.
Nutrition experts debate the reliability of nutrition studies, their typical flaws and how researchers can perform better studies moving forward.
Researchers have discovered a protein signal that promotes the growth of collateral arteries, which can provide backup if major arteries are blocked.
New Stanford research has identified an enzyme that plays a critical role in uterine contractions as well as in other muscle tissues.
A new analysis found that the National Institutes of Health is funding more conservative research projects, which does not promote great new discoveries, the authors argue.
In a study, paralyzed people with tiny brain implants were able to directly operate a tablet just by thought.
With age comes wisdom: mostly true. But a new study helps explain why one part of us - our immune system - gets decidedly dumber with age.
In this piece, Dean Lloyd Minor argues that doctors and researchers have a responsibility to educate people about the role and value of science.
DNA looping, or folding, directs a cell's developmental fate. Harnessing this 'DNA origami' could help researchers generate specific tissues for therapies.
A novel immunotherapy appears safe for use in patients with non-Hodgkin’s lymphoma. Here, a Northern California man shares his experience in the study.
The anti-inflammatory drug ketoprofen shows promise as effective medical treatment for lymphedema symptoms, small Stanford study finds
Cancerous tumors cause disease in two ways: they grow and spread. But a new immune therapy approach may be able to target both problems simultaneously.
Your trillions-strong ecosystem of gut microbes, in addition to its many other responsibilities, operates as a homespun pharmaceutical factory.
Much of what we know about the immune system comes from experiments conducted on mice. But lab mice are not little human beings. The two species are separated by both physiology and lifestyles. Stanford immunologist Mark Davis is calling on his colleagues to shift their research focus to people.
